Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Reumatologia ; 62(2): 115-120, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38799777

RESUMO

Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune disorder that affects the joints, causing inflammation, pain, and potential joint damage. Patients with RA are at high risk of developing psychiatric morbidity; it is important to recognize these psychiatric manifestations. The relationship between psychiatric symptoms and RA is complex and can involve various factors, including the impact of chronic pain, inflammation, medications, and the overall burden of managing a chronic illness.Aim of the study was to systematically investigate and analyze the patterns and prevalence of psychiatric morbidity among individuals diagnosed with RA, with the aim of identifying common mental health conditions, understanding the interplay between RA and psychiatric disorders, and providing valuable insights for improved holistic patient care. Material and methods: This was a prospective, observational cross-sectional study conducted over a period of three years in patients with RA. Psychiatric morbidity was assessed using International Classification of Diseases-10 criteria and Mini-Plus by dedicated psychiatrists. The diagnosis of RA was confirmed using the 2010 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) diagnostic criteria for RA and the disease activity was calculated by Disease Activity Score with 28-joint count (DAS28) using the calculator from the RheumaHelper application. The data were analyzed using SPSS, version 23.0. Results: A total of 1,000 patients with RA were included in this study. Nearly two-thirds of the patients were female (64.8%). The majority of patients belonged to the age group of 41 to 54 years. Total 47.5% of the patients were unemployed, 27.0% were salaried, 19.0% were businessman, while 6.5% of the patients were students. More than half of the patients (53.2%) had moderate disease activity. Major depressive disorder was the most commonly observed comorbidity (41.0%), followed by somatoform disorder (28.5%), and generalized anxiety disorder was found in 13.5%. No psychiatric manifestations were found in 17% of studied individuals. Conclusions: Psychiatric morbidity is associated with RA and there is a need for psychiatric services to be made available to these patients.

2.
Int J Rheum Dis ; 22(1): 9-24, 2019 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-30338644

RESUMO

Although anti-tumor necrosis factor (TNF) agents have greatly improved the management of rheumatic diseases, their cost limits access to many patients throughout the world. As a result, patients and clinicians have turned to biosimilars to provide similar efficacy at a lower cost. Many of the regulatory guidelines in the Asia Pacific region are largely based on those of the European Medicines Agency and the World Health Organization; however, there are variations between countries. Additionally, in some countries, intended copies are available that were approved prior to the development of guidelines and have not fulfilled the requirements of a biosimilar. We review the various regulatory requirements for biosimilars in the Asia Pacific region, the anti-TNF biosimilars and intended copies approved in the region, and whether clinical data are available for these agents. We discuss concerns about the need for additional regulations and education, and we provide recommendations for a multidisciplinary pharmacovigilance approach that closely monitors the safety of biosimilar use.


Assuntos
Antirreumáticos/uso terapêutico , Produtos Biológicos/uso terapêutico , Medicamentos Biossimilares/uso terapêutico , Desenvolvimento de Medicamentos/métodos , Doenças Reumáticas/tratamento farmacológico , Reumatologia/métodos , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Antirreumáticos/efeitos adversos , Antirreumáticos/classificação , Ásia , Austrália , Produtos Biológicos/efeitos adversos , Produtos Biológicos/classificação , Medicamentos Biossimilares/efeitos adversos , Medicamentos Biossimilares/classificação , Aprovação de Drogas , Desenvolvimento de Medicamentos/legislação & jurisprudência , Regulamentação Governamental , Humanos , Segurança do Paciente , Formulação de Políticas , Guias de Prática Clínica como Assunto , Doenças Reumáticas/diagnóstico , Doenças Reumáticas/imunologia , Reumatologia/legislação & jurisprudência , Medição de Risco , Terminologia como Assunto , Resultado do Tratamento , Fator de Necrose Tumoral alfa/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...